'Miracle particle' makes cancerous tumors disappear

Scientists have successfully created a mini drug factory, the size of a needle that can treat cancer in a few days.

The drug plant is shaped like small beads, made of alginate, each only 1.5 mm wide. When entering the body, they will join with the molecule interleukin-2 (IL-2) in the immune system to create small "explosion". This natural compound activates the body's white blood cells, which fight tumors.

1.5mm wide alginate particles are introduced into the body to treat cancer.

According to Dr. Bryan Burt, thoracic surgeon and oncologist at Baylor College of Medicine, the new therapy is suitable for people with malignant pleural mesothelioma. This is a very serious disease of the lung mucosa, difficult to definitively treat with surgical removal.

With their small size, these "miracle particles" can be delivered directly to the site of cancer-bearing tissues without affecting surrounding healthy tissue. The team also used a substance called a checkpoint inhibitor. This type of substance does not directly address cancer cells, but trains the immune system, helping to identify and eliminate cancer cells more effectively.

"Our data show that the regional distribution of the miracle particles in mice with carcinoma has very positive results. In fact, I have never seen cancerous tumors before. destroyed so quickly," Dr. Burt said.

From the results obtained, experts believe that the new method can train the body's T cells to remember and fight the carcinoma if it recurs. Previously, the IL-2 method had a similar mechanism, but with some serious side effects. Experts expect "miracle beads" to overcome this drawback.

The technique of designing mini-drug factories has been used by some researchers in the treatment of ovarian cancer. Clinical trials on humans are expected in the next few months.

"There's still a lot of work to be done, but we're certainly excited about the potential of this work. The new discovery could change the current paradigm of cancer treatment," said Omid Veiseh, a bioengineer at the University of California. Rice study, comment.